Viridian Therapeutics, Inc. VRDN Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$360.59M-5.3% | -$342.6M-13.5% | -$301.97M+12.2% | -$344.06M-11.6% | -$308.32M-14.2% | ||
| $464K+0.9% | $460K-0.6% | $463K-4.1% | $483K-5.7% | $512K-5.2% | ||
| $47.47M+7.2% | $44.3M+7.3% | $41.29M+6.5% | $38.76M-2.3% | $39.68M-5.9% | ||
| —— | —— | $4.02M-25.6% | $5.4M+347% | $1.21M+1,758% | ||
| —— | —— | —— | —— | $6.33M-70.4% | ||
| —— | —— | -$2.44M-150% | $4.84M— | —— | ||
| -$332K-111% | -$157K-100% | $69.38M+13,494% | -$518K+15.6% | -$614K+1.0% | ||
| -$303.39M-9.8% | -$276.39M+15.2% | -$325.97M-5.5% | -$309.06M-10.5% | -$279.75M-20.4% | ||
| $432K-12.7% | $495K+34.1% | $369K-31.0% | $535K-10.4% | $597K+16.8% | ||
| $599.35M+3.5% | $579.28M+79.4% | $322.86M-39.9% | $537.2M-0.6% | $540.7M-22.2% | ||
| $539.42M-0.5% | $542.21M-3.6% | $562.17M-0.7% | $565.93M+1.8% | $555.76M+19.0% | ||
| -$60.36M-60.7% | -$37.56M-116% | $238.94M+747% | $28.2M— | —— | ||
| $60.09M-7.6% | $65.03M+28.9% | $50.43M— | —— | —— | ||
| —— | $478K+33.3% | $358.5K+50.0% | $239K+100% | $119.5K— | ||
| $423.89M-0.7% | $426.74M+657% | $56.36M-80.6% | $290.52M+0.2% | $289.87M-36.7% | ||
| $60.13M-46.7% | $112.79M+468% | -$30.67M-418% | $9.66M-60.7% | $24.57M+860% | ||
| $2.82M+31.2% | $2.15M+18.5% | $1.82M0.0% | $1.82M-0.1% | $1.82M-0.2% | ||
| $6.3M-6.9% | $6.76M-17.7% | $8.21M-21.5% | $10.46M-21.5% | $13.31M-15.0% | ||
| —— | —— | —— | —— | $0— | ||
| —— | $1.75M+33.3% | $1.31M+50.0% | $875.5K+100% | $437.75K— | ||
| —— | —— | -$2.44M-150% | $4.84M— | —— | ||
| —— | —— | —— | —— | -$614K+1.0% | ||
| —— | —— | —— | —— | —— | ||
| $539.42M-0.5% | $542.21M-3.6% | $562.17M-0.7% | $565.93M+1.8% | $555.76M+19.0% | ||
| —— | $4.98M+33.3% | $3.74M+50.0% | $2.49M+100% | $1.25M— | ||
| —— | $478K+33.3% | $358.5K+50.0% | $239K+100% | $119.5K— | ||
| —— | —— | —— | —— | —— | ||
| —— | $55M+33.3% | $41.25M+50.0% | $27.5M+100% | $13.75M— | ||
| —— | —— | —— | —— | $879K+30.4% | ||
| —— | —— | —— | —— | $1.62M— | ||
| —— | $0-100% | $209.25K-50.0% | $418.5K-33.3% | $627.75K-25.0% | ||
| -$303.82M-9.7% | -$276.89M+15.2% | -$326.34M-5.4% | -$309.6M-10.4% | -$280.35M-20.4% | ||
| -$303.82M-9.7% | -$276.89M+15.2% | -$326.34M-5.4% | -$309.6M-10.4% | -$280.35M-20.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Viridian Therapeutics, Inc. generate?
- Viridian Therapeutics, Inc. (VRDN) generated -$303.4M in operating cash flow over the trailing twelve months.
- What is Viridian Therapeutics, Inc.'s free cash flow?
- After $432.0K of capital expenditures, Viridian Therapeutics, Inc.'s free cash flow was -$303.8M over the trailing twelve months, down 8.4% year over year.
- Where does Viridian Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Viridian Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
